Literature DB >> 21748246

Prognostic significance of lymph node metastases in patients with high-grade appendiceal cancer.

Hatem El Halabi1, Vadim Gushchin, Jennifer Francis, Nicholas Athas, Ryan Macdonald, Carol Nieroda, Kimberly Studeman, Armando Sardi.   

Abstract

BACKGROUND: In treating high-grade appendiceal cancer, appropriate patient selection for cytoreductive surgery and heated intraperitoneal chemotherapy (CRS/HIPEC) is essential. The effect of lymph node (LN) status on survival is not clear. We hypothesize that LN metastases negatively affect long-term survival.
METHODS: Retrospective analysis of peritoneal mucinous carcinomatosis (PMCA) patients from a prospective database was conducted. Using Kaplan-Meier survival curves and Cox proportional hazards ratio analysis, the effect of LN status, completeness of cytoreduction (CC), and peritoneal cancer index (PCI) was studied.
RESULTS: Of 134 patients with appendiceal cancer who underwent CRS/HIPEC, 77 (57%) had PMCA. Mean follow-up was 22 (range, 3-90) months. Overall survival (OS) was 88, 56, and 40% for 1, 3, and 5-year, respectively. Thirty-four patients (44%) had LN metastases, 23 of whom (68%) had CC, whereas in LN negative patients 35 of 43 (81%) had CC (p = 0.191). PCI ≥ 20 was seen in 23 of 34 patients (68%) with LN metastases and 29 of 43 (67%) without metastases (p = 0.191). Five-year OS for patients with LN metastases was 11% compared with 76% for LN negative (p < 0.001). Among patients with complete cytoreduction, 5-year OS for LN positive vs. negative was 21 and 73%, respectively (p = 0.002). On multivariate regression analysis of LN status, CC score and PCI, the following hazard ratios were obtained: 3.4 (95% confidence interval (CI), 1.3-9.0), 2.6 (95% CI, 1.03-6.7), and 2.8 (95% CI, 0.8-10.4), respectively.
CONCLUSIONS: Patient selection for CRS/HIPEC should take into consideration LN status, but it should not be a contraindication if preoperative evaluation revealed a high likelihood of complete cytoreduction.

Entities:  

Mesh:

Year:  2011        PMID: 21748246     DOI: 10.1245/s10434-011-1903-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  11 in total

Review 1.  Surgical treatment of peritoneal carcinomatosis: current treatment modalities.

Authors:  Yakup Kulu; Beat Müller-Stich; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2013-11-19       Impact factor: 3.445

2.  Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases.

Authors:  Konstantinos I Votanopoulos; Greg Russell; Reese W Randle; Perry Shen; John H Stewart; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2014-10-16       Impact factor: 5.344

3.  Peritoneal carcinomatosis of gastrointestinal tumors: where are we now?

Authors:  Cem Terzi; Naciye Cigdem Arslan; Aras Emre Canda
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

4.  Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries.

Authors:  Harveshp D Mogal; Edward A Levine; Greg Russell; Perry Shen; John H Stewart; Konstantinos I Votanopoulos
Journal:  Ann Surg Oncol       Date:  2015-08-20       Impact factor: 5.344

5.  Peritoneal dissemination from high-grade appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).

Authors:  Kathleen A Cummins; Gregory B Russell; Konstantinos I Votanopoulos; Perry Shen; John H Stewart; Edward A Levine
Journal:  J Gastrointest Oncol       Date:  2016-02

Review 6.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a review of factors contributing to morbidity and mortality.

Authors:  Andrew D Newton; Edmund K Bartlett; Giorgos C Karakousis
Journal:  J Gastrointest Oncol       Date:  2016-02

Review 7.  Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future.

Authors:  Ahmed Dehal; J Joshua Smith; Garrett M Nash
Journal:  J Gastrointest Oncol       Date:  2016-02

8.  Progression of peritoneal adenomucinosis to the scrotum: a rare occurrence treated with cytoreductive surgery and hyperthermic chemoperfusion of the scrotum in two patients.

Authors:  Armando Sardi; William Andrés Jiménez; Chukwuemeka Wosu
Journal:  Colomb Med (Cali)       Date:  2014-06-30

Review 9.  The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies.

Authors:  Mackenzie C Morris; Jordan M Cloyd; John Hays; Sameer H Patel
Journal:  J Gastrointest Surg       Date:  2020-08-17       Impact factor: 3.452

10.  A core microbiome associated with the peritoneal tumors of pseudomyxoma peritonei.

Authors:  Jeremy J Gilbreath; Cristina Semino-Mora; Christopher J Friedline; Hui Liu; Kip L Bodi; Thomas J McAvoy; Jennifer Francis; Carol Nieroda; Armando Sardi; Andre Dubois; David W Lazinski; Andrew Camilli; Traci L Testerman; D Scott Merrell
Journal:  Orphanet J Rare Dis       Date:  2013-07-12       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.